1
|
Narayanasamy S, Curtis LH, Hernandez AF, Woods CW, Moody MA, Sulkowski M, Turbett SE, Baden LR, Gulick RM, Pau AK, Adam SJ, Marks P, Stockbridge NL, Dobbins JR, Krofah E, Leav B, Pang P, Roessig L, Vedin O, Waldstreicher J, Berman SC, Cremisi H, Schofield L, Gandhi RT, Naggie S. Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank. Clin Infect Dis 2023; 77:1635-1643. [PMID: 37435958 PMCID: PMC10724451 DOI: 10.1093/cid/ciad418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Revised: 06/07/2023] [Accepted: 07/10/2023] [Indexed: 07/13/2023] Open
Abstract
While the coronavirus disease 2019 (COVID-19) pandemic continues to present global challenges, sufficient time has passed to reflect on lessons learned and use those insights to inform policy and approaches to prepare for the next pandemic. In May 2022, the Duke Clinical Research Institute convened a think tank with thought leaders from academia, clinical practice, the pharmaceutical industry, patient advocacy, the National Institutes of Health, the US Food and Drug Administration, and the Centers for Disease Control and Prevention to share, firsthand, expert knowledge of the insights gained from the COVID-19 pandemic and how this acquired knowledge can help inform the next pandemic response. The think tank focused on pandemic preparedness, therapeutics, vaccines, and challenges related to clinical trial design and scale-up during the early phase of a pandemic. Based on the multi-faceted discussions, we outline 10 key steps to an improved and equitable pandemic response.
Collapse
Affiliation(s)
- Shanti Narayanasamy
- Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, USA
- Hubert-Yeargan Center for Global Health, Duke University, Durham, North Carolina, USA
| | - Lesley H Curtis
- Duke Clinical Research Institute, Durham, North Carolina, USA
- Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA
| | - Adrian F Hernandez
- Duke Clinical Research Institute, Durham, North Carolina, USA
- Division of Cardiology, Department of Medicine, Duke University, Durham, North Carolina, USA
| | - Christopher W Woods
- Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, USA
- Hubert-Yeargan Center for Global Health, Duke University, Durham, North Carolina, USA
| | - M Anthony Moody
- Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA
- Duke Human Vaccine Institute, Durham, North Carolina, USA
| | - Mark Sulkowski
- Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | - Sarah E Turbett
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
| | | | | | - Alice K Pau
- National Institutes of Health, Bethesda, Maryland, USA
| | - Stacey J Adam
- Foundation for the National Institutes of Health, North Bethesda, Maryland, USA
| | - Peter Marks
- US Food and Drug Administration, Silver Spring, Maryland, USA
| | | | | | - Esther Krofah
- FasterCures & Center for Public Health, Milken Institute, Washington, DC, USA
| | | | - Phil Pang
- Vir Biotechnology, Inc, San Francisco, California, USA
| | | | - Ola Vedin
- Boehringer Ingelheim AB, Stockholm, Sweden
| | | | | | | | - Lesley Schofield
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
| | - Rajesh T Gandhi
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
| | - Susanna Naggie
- Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina, USA
- Duke Clinical Research Institute, Durham, North Carolina, USA
| |
Collapse
|
3
|
Rodewald L, Wu D, Yin Z, Feng Z. Vaccinate with Confidence and Finish Strong. China CDC Wkly 2022; 4:828-831. [PMID: 36284540 PMCID: PMC9547736 DOI: 10.46234/ccdcw2022.172] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2022] [Accepted: 08/30/2022] [Indexed: 12/04/2022] Open
Affiliation(s)
- Lance Rodewald
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Dan Wu
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zundong Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zijian Feng
- Chinese Center for Disease Control and Prevention, Beijing, China
- Chinese Preventive Medicine Association, Beijing, China
| |
Collapse
|
4
|
Herrera CM, Schmitt JS, Chowdhry EI, Riddle MS. From Kiyoshi Shiga to Present-Day Shigella Vaccines: A Historical Narrative Review. Vaccines (Basel) 2022; 10:645. [PMID: 35632401 PMCID: PMC9145194 DOI: 10.3390/vaccines10050645] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2022] [Revised: 03/20/2022] [Accepted: 04/18/2022] [Indexed: 02/06/2023] Open
Abstract
We are at an exciting moment in time with the advancement of many vaccines, including a shigella vaccine for the world. It is instructive to look at the long road that some vaccines have traveled to recognize the remarkable accomplishments of those who were pioneers, appreciate the evolution of scientific and applied technology, and inform the future history of a vaccine that would have great potential for global health. To achieve this valuable retrospective, a narrative historical literature review was undertaken utilizing PubMed and Embase databases with relevant search terms. Retrieved articles were reviewed and information was organized into historical themes, landmark discoveries, and important vaccine development parallels. The literature reviewed was synthesized into major eras of shigella vaccine development from pathogen discovery and first attempts to empirical approaches of killed whole-cell and live-attenuated approaches, and a modern era that applied recombinant DNA engineering and structural vaccinology. The history of shigella vaccine development has largely followed the evolutionary path of vaccine development over the last 120 years, but with important lessons learned that should be considered as we embark on the future chapters of bringing to the world a safe and effective vaccine for global health.
Collapse
Affiliation(s)
| | | | | | - Mark S. Riddle
- Reno School of Medicine, University of Nevada, Reno, NV 89557, USA; (C.M.H.); (J.S.S.); (E.I.C.)
| |
Collapse
|
5
|
How Do People Decide on Getting Vaccinated? Evaluating the COVID-19 Vaccination Program through the Lens of Social Capital Theory. SOCIAL SCIENCES-BASEL 2022. [DOI: 10.3390/socsci11040145] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The COVID-19 pandemic has disrupted economies at a scale unprecedented in recent history, and vaccination is deemed the only option to ultimately halt its spread. However, vaccine hesitancy remains a global issue that must be addressed. If left unaddressed, it will impede the recovery of both the economy and public health following the pandemic. To better understand the issue, on the premise that individuals have layers of social ties to achieve common goals, social capital theory is proposed to examine the social connections associated with vaccine acceptance. A case study of the Republic of the Philippines’ vaccination program, in the form of an online survey involving 430 participants, was conducted using logistic binomial regression to analyze the data. Findings reveal that people’s vaccination decisions are influenced by their perceptions of their social ties regarding the vaccines, such as the perceptions one’s social ties’ trust in the vaccines, safety of use, benefits vaccines can offer, the role of media in information dissemination, and the influence of social networks. Insights regarding these findings are also discussed.
Collapse
|
7
|
An Z, Wang F, Pan A, Yin Z, Rodewald L, Feng Z. Vaccination strategy and challenges for consolidating successful containment of covid-19 with population immunity in China. BMJ 2021; 375:e066125. [PMID: 34853010 PMCID: PMC8634348 DOI: 10.1136/bmj-2021-066125] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Zijian Feng and colleagues argue that sustained elimination of SARS-CoV-2 in China offers flexibility in covid-19 vaccination policy and discuss the anticipated challenges and systematic monitoring necessary to keep the immunisation component of the response on track
Collapse
Affiliation(s)
- Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Fuzhen Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - An Pan
- School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Zundong Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lance Rodewald
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zijian Feng
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
- Chinese Preventive Medicine Association, Beijing, China
| |
Collapse
|
8
|
Equitable allocation of COVID-19 vaccines in the United States. Nat Med 2021; 27:1298-1307. [PMID: 34007071 DOI: 10.1038/s41591-021-01379-6] [Citation(s) in RCA: 52] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Accepted: 04/29/2021] [Indexed: 02/04/2023]
Abstract
Many vaccine rationing guidelines urge planners to recognize, and ideally reduce, inequities. In the United States, allocation frameworks are determined by each of the Centers for Disease Control and Prevention's 64 jurisdictions (50 states, the District of Columbia, five cities and eight territories). In this study, we analyzed vaccine allocation plans published by 8 November 2020, tracking updates through to 30 March 2021. We evaluated whether jurisdictions adopted proposals to reduce inequity using disadvantage indices and related place-based measures. By 30 March 2021, 14 jurisdictions had prioritized specific zip codes in combination with metrics such as COVID-19 incidence, and 37 jurisdictions (including 34 states) had adopted disadvantage indices, compared to 19 jurisdictions in November 2020. Uptake of indices doubled from 7 to 14 among the jurisdictions with the largest shares of disadvantaged communities. Five applications were distinguished: (1) prioritizing disadvantaged groups through increased shares of vaccines or vaccination appointments; (2) defining priority groups or areas; (3) tailoring outreach and communication; (4) planning the location of dispensing sites; and (5) monitoring receipt. To ensure that equity features centrally in allocation plans, policymakers at the federal, state and local levels should universalize the uptake of disadvantage indices and related place-based measures.
Collapse
|